What the 2019 musculoskeletal review actually claims about BPC-157

The 2019 review in Cell and Tissue Research is the paper most often paraphrased when BPC-157 is described as a tendon-healing peptide. It is a narrative review, not a meta-analysis with a pooled effect size. The authors walk through musculoskeletal soft-tissue experiments, starting from the gastric pentadecapeptide sequence and the earlier Sikiric literature, and they give special attention to tendon.

The Achilles experiment underneath the review

One anchor study is Staresinic and colleagues, 2003: rat Achilles tendons were transected, and animals received intraperitoneal BPC-157 at microgram-to-picogram per kilogram doses or saline. The peptide group showed higher failure load, a better Achilles functional index, and histologic signs of more organized repair. Those doses and that route are facts about a rat experiment. They are not a human protocol, and this journal will not reprint them as one.

Routes, and the gap the reviewers name

The review also describes ligament work, including Cerovecki 2010, in which the peptide was given by more than one route over a long animal follow-up. The reviewers’ caution is the part summaries drop. Local delivery, biomechanics in small animals, and the absence of a completed clinical package still stand between these models and routine human use. A fair review of the review keeps that sentence.